Oropharyngeal candidiasis (OPC) is considered the most common fungal infection in human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients. Antifungal drug, azole group, is the preferred treatment. However, the long-term use of antifungal drug as prophylaxis and therapy for OPC may lead to a compromised side effects and drug resistance. Nowadays, the prevalence of antifungal Candida albicans resistance is approximately 56.7%. Ellagic acid (EA) presents broad spectrum of antifungal activities. Based on previous studies, EA can act as natural antifungal agent. It also helps enhancing oral mucosal innate immunity. This review explores the antifungal activity of EA as an alternative for antifungal drugs resistance in HIV/AIDS patients with OPC. A web-based search was conducted via PubMed, NCBI, Scopus, ScienceDirect, and Research-Gate databases, with "antifungal resistance", "ellagic acid", "HIV/AIDS", and "OPC" as the keywords. EA is a dimeric derivative of gallic acid that is found in several plants. EA can induce the expression of hBD2 and SLPI in the oral mucosa. Those proteins play a pivotal role in immunomodulation and anti-inflammation of oral microenvironment innate immunity, which inhibit several opportunistic pathogens and microbes, including Candida. Furthermore, EA also inhibits ergosterol biosynthesis (EB), which is the primary component of fungi cell membrane. EA breakdown fungal membrane permeability and enzyme activity, leading to cessation of fungal growth. EA presents antifungal activity in HIV/AIDS patients with OPC; thus, it can be used as an alternative in antifungal drug resistance.

Background: Dental caries is the most common multifactorial disease in the world. In saliva of caries patients, occur an increase in innate immunity, such as human beta defensin-2 (HBD-3) and human beta defensin-2 (HBD-3). Research on quantification the molecular weight of HBD-2 and HBD-3 in saliva of caries patients has not done yet. Objective: Determine the molecular weight from HBD-2 and HBD-3 from saliva of caries patients using the Western Blot method. Method: This study was approved by the Health Research Ethical Clearance Commission of Faculty of Dental Medicine Airlangga University No.156/HRECC.FODM/IV/2019. After every individual agreed, saliva sample from 16 children with caries and caries-free in the Dental Hospital Airlangga University was collected in June to July 2019. Male/female aged 9-12 years and DMF-t > 5, taken 5 ml of saliva between 8-10 o'clock, passive-drool method without stimulation. Salivary samples were centrifuged for 20 minutes, 4ºC, with 10.000 rpm. Total protein was calculated using bicinchoninic acid (BCA) Assays before loading into Sodium Dodecyl Sulfate PolyAcrilamide Gel Electrophoresis (SDS-PAGE) to evaluate protein separation based on molecular weight. Furthermore, Western Blot is performed to ensure the protein that appears is HBD-2 and HBD-3 specific protein using primary and secondary antibodies. Results: THE molecular weight of HBD-2 and HBD-3 in the saliva of caries patients is 43 kDa, while the salivary free-caries band in the gel is unreadable, thus the molecular weight cannot be determined. Conclusion: The molecular weight of HBD-2 and HBD-3 in the saliva of caries patients calculated using the Western Blot method was 43 kDa.